Glucagon vs Dasiglucagon

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicGlucagonDasiglucagon
What it is

A peptide hormone. The label states that glucagon raises blood sugar by activating glucagon receptors in the liver, which releases stored glucose.1

A synthetic glucagon analogue of 29 amino acids that activates glucagon receptors in the liver, according to the Zegalogue label.6

FDA status

FDA-approved

FDA-approved as Gvoke, Baqsimi and other glucagon products1,2,3,4

FDA-approved. Drugs@FDA lists the first glucagon application with an approval date of November 14, 1960, and Gvoke with an approval date of September 10, 2019. The cited label has no boxed warning.1,2,4

Is glucagon FDA-approved?

FDA-approved

FDA-approved as Zegalogue for severe low blood sugar; discontinued5,6

FDA-approved, but discontinued. Drugs@FDA lists Zegalogue, NDA 214231, with an original approval date of March 22, 2021, and lists both of its products as discontinued.5

Is dasiglucagon FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.7

Not among the six peptides the policy lists.7

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Dasiglucagon is not among them.7,8

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list dasiglucagon.9

Kinds of studies cited

Smaller controlled human trials

  • Controlled human trial Two multicenter randomized crossover studies in adults with type 1 diabetes (80 and 81 participants) that compared Gvoke with another glucagon product after blood sugar was lowered with insulin.1
  • Small, short, or incompletely reported human study A study in 31 children with type 1 diabetes, all evaluable participants of whom reached the target rise in blood sugar.1

Smaller controlled human trials

  • Controlled human trial Trial A (NCT03378635): a randomized, double-blind trial in 170 adults with type 1 diabetes comparing dasiglucagon with placebo and with glucagon after induced low blood sugar, described in the label.6
Records collected

31 ClinicalTrials.gov records and 255 PubMed records collected

16 ClinicalTrials.gov records and 2 PubMed records collected

Area of study

Metabolic and weight1

Metabolic and weight6

Latest dated events
  1. DailyMed publishes the Gvoke and Gvoke VialDx label version cited on this page.1
  2. FDA approves Gvoke, according to Drugs@FDA.4
  3. FDA approves Baqsimi, according to Drugs@FDA.3
  1. DailyMed publishes the Zegalogue label version cited on this page.6
  2. FDA approves Zegalogue, NDA 214231, according to Drugs@FDA.5

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    GVOKE VIALDX (glucagon) injection, solution · SPL version 2 · published 2026-07-09 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    Drugs@FDA application NDA012122 · original submission status AP · 1960-11-14 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  3. 3
    Drugs@FDA application NDA210134 · original submission status AP · 2019-07-24 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  4. 4
    Drugs@FDA application NDA212097 · original submission status AP · 2019-09-10 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Drugs@FDA: ZEGALOGUE (dasiglucagon hydrochloride), NDA 214231 · original approval March 22, 2021 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  6. 6
    ZEGALOGUE (dasiglucagon) injection · SPL version 3 · published 2026-06-17 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  7. 7
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  8. 8
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  9. 9
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026